# A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

> **NCT01486017** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 30 (actual)

## Conditions studied

- Bioavailability of ASP015K
- Pharmacokinetics of ASP015K
- Healthy Subjects

## Interventions

- **DRUG:** ASP015K

## Key facts

- **NCT ID:** NCT01486017
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486017, "A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01486017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*